Balixafortide TFA (POL6326 TFA) is a potent, selective, and well-tolerated peptidic CXCR4 antagonist with an IC50 less than 10 nM. It demonstrates significant selectivity for CXCR4, approximately 1000-fold, over various other receptors including CXCR7. This compound effectively blocks β-arrestin recruitment and calcium flux with IC50s less than 10 nM, functioning as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent with observed anti-cancer effects.
- Potent and selective CXCR4 antagonist
- Demonstrates high selectivity over other receptors like CXCR7
- Blocks β-arrestin recruitment and calcium flux
- Functions as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent
- Exhibits anti-cancer effects
- Optimized for favorable mouse ADME properties